After participating in this symposium, the learner will be able to:

Characterize type 2 diabetes as a cardiovascular risk factor

Outline key aspects of care for a patient with type 2 diabetes

Compare the classes of medications generally recommended for use in combination with metformin

Differentiate traditional clinical outcomes trials from cardiovascular safety trials

Describe the findings of cardiovascular safety trials demonstrating cardiovascular benefit

Select pharmacologic treatment for use in combination with metformin that includes consideration of cardiovascular safety and benefit

The Illinois Academy of Family Physicians (IAFP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 - The Illinois Academy of Family Physicians designates this live activity, A New Paradigm Shift in CV Risk Reduction in T2DM, for a maximum of 1.00 AMA PRA Category 1 credit™.
NPs and PAs: The American Association of Nurse Practitioners and The American Academy of Physician Assistants accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Instructions on how to receive your certificate will be available at the end of the webinar.


The Illinois Academy of Family Physicians adheres to the conflict of interest policy of the ACCME and the AMA. It is the policy of Illinois AFP to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All individuals in a position to control the content in our programs are expected to disclose any relationships they may have with commercial companies whose products or Services may be mentioned so that participants may evaluate the objectivity of the presentations. In addition, any discussion of off-label, experimental, or investigational use of drugs or devices will be disclosed by the faculty. Only those participants who have no conflict of interest or who agree to an identified resolution process prior to their participation were involved in the CME activity.

This program does not include any discussion or demonstration of any pharmaceuticals or medical devices that are not approved by the Food and Drug Administration (FDA) or that are considered “off-label.”

Davida F. Kruger, MSN, APN-BC, BC-ADM, discloses that she is on the advisory board and speaker’s bureau for Abbott, Dexcom, Eli Lilly and Company, Janssen and Novo Nordisk. She’s on the advisory board for Intarcia and Sanofi and on the speakers bureau for AstraZeneca, BI/Lilly and Valeritas. She does Grants / Research Support to the Henry Ford Health System for AstraZeneca, Dexcom, Eli Lilly, Hemsley Foundation, Lexicon, and Novo Nordisk. She owns stock in Dexcom. John G. McGinnity MS, PA-C, DFAAPA, faculty disclosed no relevant financial relationship or interest with a proprietary entity producing, marketing, reselling or distributing health care goods or services, as does Gregory Scott, PharmaD, Rph, Editorial Support and Allan Wilke, MD, CME Reviewer. Stephen Brunton MD, FAAFP, Reviewer, discloses that he is on the advisory board for Abbott Diabetes and Becton Dickinson. He is on the advisory board and speakers’ bureau for AstraZeneca, Boehringer Ingelheim, Janssen, Lilly and Novo Nordisk. Additional staff of Primary Care Education Consortium and IAFP disclosed no relevant financial relationship or interest with a proprietary entity producing, marketing, reselling or distributing health care goods or services.